Skip to main content
. 2026 May 13;26:1259. doi: 10.1186/s12903-026-08538-6

Table 6.

Group 2 correlation analyses

Parameters Serum
MMP-8 (ng/Ml)		 GCF MMP-8
(ng/Ml)		 Serum
OPG
(ng/mL)		 GCF
OPG
(ng/mL)		 Serum RANKL (pg/mL) GCF
RANKL (pg/mL)		 Serum MDA
(nmol/mL)		 Serum
GSH
(mM)		 PI GI BOP
(%)		 PPD
(mm)		 CAL
(mm)		 TAS TOS OSI Serum
RANKL/OPG
GCF MMP-8 (ng/Ml) r 0.053 --
p 0.677
Serum OPG (ng/mL) r -0.131 -0.101 --
p 0.305 0.429
GCF OPG (ng/mL) r 0.107 -0.002 -0.051 --
p 0.404 0.989 0.693
Serum RANKL (pg/mL) r − 0.313 * 0.161 0.090 -0.160 --
p 0.013 0.209 0.481 0.209
GCF RANKL (pg/mL) r -0.066 -0.145 -0.014 -0.095 0.036 --
p 0.609 0.256 0.916 0.459 0.777
Serum MDA (nmol/mL) r 0.125 − .408** 0.271 * -0.239 -0.078 0.129 --
p 0.327 0.001 0.032 0.059 0.541 0.315
Serum GSH (mM) r -0.069 -0.196 0.017 -0.132 0.193 0.179 0.018 --
p 0.589 0.123 0.896 0.303 0.129 0.160 0.888
PI r 0.066 -0.086 0.092 -0.135 -0.196 0.083 0.341 ** 0.082 --
p 0.605 0.505 0.472 0.293 0.124 0.520 0.006 0.525
GI r 0.055 -0.067 0.199 -0.148 -0.104 0.105 0.369** -0.105 0.666** --
p 0.669 0.603 0.117 0.246 0.419 0.415 0.003 0.414 0.000
BOP (%) r 0.101 -0.129 0.219 − 0.258 * -0.111 0.107 0.481 ** -0.139 0.623** 0.818** --
p 0.431 0.314 0.085 0.041 0.385 0.404 0.000 0.279 0.000 0.000
PPD (mm) r 0.273 * -0.165 -0.040 0.000 -0.141 0.029 0.268 * 0.025 0.308 * 0.364 ** 0.393 ** --
p 0.030 0.197 0.753 0.997 0.270 0.824 0.034 0.843 0.014 0.003 0.001
CAL(mm) r 0.276 * -0.163 -0.057 0.047 -0.049 -0.024 0.325 ** 0.073 0.319 * 0.320 * 0.350 ** 0.900 ** --
p 0.028 0.201 0.656 0.716 0.701 0.855 0.009 0.571 0.011 0.010 0.005 0.000
TAS r 0.002 0.198 -0.154 -0.044 0.207 -0.124 − 0.330 ** -0.050 − 0.328 ** -0.111 -0.096 0.066 0.069 --
p 0.990 0.120 0.228 0.733 0.103 0.334 0.008 0.700 0.009 0.387 0.456 0.606 0.589
TOS r 0.022 -0.101 0.182 -0.013 -0.081 0.148 0.375 ** 0.047 -0.058 -0.129 0.063 -0.037 0.003 − 0.289 * --
p 0.863 0.433 0.154 0.917 0.530 0.248 0.002 0.713 0.654 0.315 0.621 0.776 0.981 0.022
OSI r 0.023 -0.118 0.064 -0.003 -0.131 0.140 0.456 ** 0.122 0.149 0.013 0.053 0.007 0.078 − 0.496 ** 0.562 ** --
p 0.858 0.358 0.619 0.983 0.307 0.275 0.000 0.340 0.242 0.921 0.678 0.959 0.545 0.000 0.000
Serum RANKL/OPG r -0.151 0.181 − 0.438 ** -0.116 0.782** 0.052 -0.166 0.171 -0.123 -0.181 -0.236 -0.111 -0.041 0.206 -0.243 -0.146 --
p 0.237 0.156 0.000 0.367 0.000 0.684 0.194 0.180 0.335 0.157 0.063 0.387 0.748 0.105 0.055 0.255
GCF RANKL/OPG r -0.116 -0.051 0.031 − 0.955 ** 0.150 0.337 ** 0.261 * 0.190 0.164 0.158 0.266 * -0.006 -0.056 0.013 0.077 0.048 0.121
p 0.364 0.692 0.807 0.000 0.241 0.007 0.039 0.135 0.199 0.217 0.035 0.962 0.663 0.918 0.550 0.708 0.343

Numbers in bold indicate a statistically significant difference

*; p < 0.05, **; p < 0.01, r Spearman correlation coefficient, PI plaque index, GI gingival index; BOP bleeding on probing, PPD probing pocket depth, CAL clinical attachment loss, GCF gingival crevicular fluid, RANKL nuclear factor kappa-B ligand, OPG osteoprotegrin, MMP-8 matrix metalloproteinase-8, MDA malondialdehyde, GSH glutathione, TOS total oxidant status, TAS total antioxidant status, OSI oxidative stress index, RA rheumatoid arthritis, Group 1; individuals with RA and periodontitis who were not receiving anti-TNF-α therapy, Group 2; individuals with RA and periodontitis under anti-TNF-α treatment for a minimum duration of one year